Amgen stops ganitumab pancreatic cancer study

Thursday 9 August 2012

Amgen has stopped a Phase 3 trial of its monoclonal antibody for metastatic pancreatic cancer after the independent data monitoring committee concluded the drug was unlikely to show improved overall survival compared with gemcitabine.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United States